Soluble TNF Receptors Are Associated with Infarct Size and Ventricular Dysfunction in ST-Elevation Myocardial Infarction

Lennart Nilsson¹,²*, Aleksander Szymanowski¹,²*, Eva Swahn¹,², Lena Jonasson¹,²

¹ Division of Cardiology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, ²Department of Cardiology, University Hospital, Linköping, Sweden

Abstract

Objectives: The aim of the study was to investigate circulating markers of apoptosis in relation to infarct size, left ventricular dysfunction and remodeling in an ST-elevation myocardial infarction (STEMI) population undergoing primary percutaneous coronary intervention (PCI).

Background: Immediate re-opening of the acutely occluded infarct-related artery via primary PCI is the treatment of choice in STEMI to limit ischemia injury. However, the sudden re-initiation of blood flow can lead to a local acute inflammatory response with further endothelial and myocardial damage, so-called reperfusion injury. Apoptosis is suggested to be a key event in ischemia-reperfusion injury, resulting in LV-dysfunction, remodeling and heart failure.

Methods: The present study is a prespecified substudy of the F.I.R.E. trial. We included 48 patients with STEMI undergoing primary PCI. Blood samples were collected prior to PCI and after 24 hours. Plasma was separated for later analysis of soluble tumor necrosis factor receptor (sTNFR) 1, sTNFR2, sFas and sFas ligand (sFasL) by ELISA. Infarct size, left ventricular (LV) dysfunction and remodeling were assessed by cardiac magnetic resonance imaging at five days and four months after STEMI.

Results: The levels of sTNFR1 at 24 h as well as the relative increases in sTNFR1 and sTNFR2 over 24 h showed consistent and significant correlations with infarct size and LV-dysfunction at four months. Moreover, both sTNFRs correlated strongly with Troponin I and matrix metalloproteinase (MMP)-2 measurements. Soluble Fas and sFasL did not overall correlate with measures of infarct size or LV-dysfunction. None of the apoptosis markers correlated significantly with measures of remodeling.

Conclusions: In STEMI patients, circulating levels of sTNFR1 and sTNFR2 are associated with infarct size and LV dysfunction. This provides further evidence for the role of apoptosis in ischemia-reperfusion injury.

Introduction

Coronary artery disease (CAD) is the leading cause of death in the western world. In many patients the first clinical presentation of CAD is an acute myocardial infarction. Immediate re-opening of the acutely occluded infarct-related artery via primary percutaneous coronary intervention (PCI) is the treatment of choice to limit ischemic injury in the setting of ST-elevation myocardial infarction (STEMI) [1,2]. However, the sudden re-initiation of blood flow achieved with primary PCI can give rise to further endothelial and myocardial damage, so-called reperfusion injury [3,4].

Ischemia and reperfusion associated myocardial injury (IR-injury) involves a wide range of pathological processes. Vascular leakage, activation of cell death programs, transcriptional reprogramming, no reflow phenomenon and innate and adaptive immune activation all contribute to tissue damage, thereby determining the infarct size [5]. Cell death programs include apoptosis, necrosis and autophagy associated cell death. Apoptosis has been implicated in each step ranging from myocardial IR-injury, to left ventricular dysfunction and remodelling, and to the development of end-stage heart failure [6–9]. In a recent study from our group, we found that early elevations of matrix metalloproteinase (MMP)-2 in plasma correlated strongly with infarct size and left ventricular dysfunction in a STEMI population, indicating that MMP-2 might play an important role in IR-injury [10]. Indeed, experimental studies and animal models
have demonstrated various mechanisms, including apoptosis, by which MMP-2 activation can mediate IR-injury [11].

There are two major pathways for apoptosis: the intrinsic mitochondrial pathway and the extrinsic pathway, involving the binding of soluble or cell membrane-bound ligands to cell surface receptors [12]. Feedback loops aiming at limiting the apoptotic rate include down regulation of the transmembrane receptor and shedding of its extracellular part, which through binding to circulating ligands can limit ligand-transmembrane receptor interaction [13]. Among these circulating markers of apoptosis, soluble Fas (sFas), and soluble tumor necrosis factor receptor 1 (sTNFR1) are elevated in patients with acute myocardial infarction [14–16], with some clinical evidence of the latter being both a predictor of the development of heart failure and of overall mortality [15,16].

This study is a pre-specified substudy of the F.I.R.E. trial, which studied the effects of the fibrin –derived peptide BP15-42 (FX06) on reperfusion injury in patients undergoing primary PCI for STEMI [17,18]. Infiltration and activation of leukocytes is an important event in myocardial reperfusion injury [3,19–21]. FX06 is a naturally occurring fragment of fibrin, which binds to the VE-cadherin receptor on endothelial cells, thereby inhibiting leukocyte transmigration through gap junctions and tissue inflammation injury [22,23]. The positive effects of FX06 on the inflammatory response are demonstrated by a decrease in cytokines and interleukins following coronary occlusion and reperfusion in pigs [24]. In occlusion-reperfusion studies in rats, administration of FX06 caused a significant 40% reduction in infarct size compared to placebo [23].

Cardiac magnetic resonance imaging (CMR) has consistently been found to accurately determine the size of myocardial infarct as well as left ventricular volumes used to calculate measures of left ventricular dysfunction and remodelling [25]. They all reflect the extent of myocardial ischemia-reperfusion injury and are strongly associated with poor prognosis [26].

The aim of this study was to analyze the circulating levels of apoptosis markers, sTNFR1, sTNFR2, sFas and sFasl, in STEMI patients prior to and 24 hours after primary PCI. Furthermore, we wanted to investigate potential correlations between these biomarkers and measures of infarct size, left ventricular dysfunction and remodelling as assessed by CMR. Lastly, we aimed to study the effect of FX-06 on soluble markers of apoptosis.

Methods

Study Population

This study is a pre-specified substudy of the F.I.R.E. trial. The study design and results of the F.I.R.E. trial (http://clinicaltrials.gov, NCT00326976) have been published elsewhere [17,18]. In brief, the F.I.R.E. trial was a double-blind, randomized, placebo-controlled multicentre-trial performed in 2006–2008, including 234 patients, to study the effects of FX06 on reperfusion damage in patients undergoing primary PCI for STEMI presenting within 6 hours from onset of symptoms. No treatment differences attributable to FX06 were observed in primary or secondary outcome measures [18]. The present substudy was designed by three of the authors (LN, LJ, ES). Complete sample sets were obtained from 46 subjects at 10 of the participating sites. Aside from study medication, patients were treated according to current ESC STEMI guidelines [27]. The study subjects received aspirin (n = 45, 98%), clopidogrel (n = 46, 100%), beta blockers (n = 46, 100%) and glycoprotein IIb/IIIa-inhibitors (n = 36, 78%).

Ethical Considerations

The study protocol was approved by all local ethic committees of the participating sites and written informed consent was obtained from all patients.

CMR Imaging

The CMR protocol has previously been described in detail [18]. All CMR studies were analyzed at the central MR Evaluation Centre, University Hospital Basel (Basel, Switzerland) by a single experienced CMR reader who was blinded to study groups followed by a blinded review by a level III CMR expert. Intraobserver variability was assessed for the primary reader in a subset of 40 randomly chosen studies and the intraclass correlation was 0.85 for 26 studies from day 5.

Biochemical Analysis

Blood samples for analysis of sTNFR1, sTNFR2, sFas, sFasl, MMPs, tissue inhibitors of metalloproteinases (TIMPs) and myeloperoxidase (MPO) were collected in vacutainer tubes (using sodium heparin as anticoagulant) at baseline immediately before primary PCI and at 24 hours. Samples were centrifuged within 30 minutes to separate plasma, which then was stored immediately at −20°C and within a week at −70°C until analyzed. Soluble TNFR1, sTNFR2, sFas and sFasl were analyzed using commercially available ELISA kit (R&D Systems Europe, Abingdon, United Kingdom). The lower limits of detection were 0.8 pg/ml (sTNFR1), 0.6 pg/ml (sTNFR2), <20 pg/ml (sFas), and 2.7 pg/ml (sFasl), respectively. The interassay CV’s ranged from 0.6–5.1% for sTNFR1, 5.7–10.4% for sTNFR2, 2.4–4.5% for sFas, and 1.5–2.4% for sFasl. Plasma levels of MMPs, TIMPs and MPO were analyzed as previously described [10]. Blood samples for Troponin I (cTnI) were obtained at 24 and 48 hours after admission to hospital. All samples were analyzed in a blinded core laboratory (Spranger Laboratories, Ingolstadt, Germany). cTnI was measured on the Abbott AxSYM System (Abbott Diagnostics, Abbott Park, Ill, US) using the second-generation AxSYM Troponin-I ADV assay. The lower limit of detection of the assay is 0.020 ng/ml with a 10% CV value of 0.16 ng/ml.

Statistical Methods

Based on previous data, we calculated that a sample size of 21 subjects in each treatment group (42 subjects in total) would be sufficient to give 80% power to detect an estimated 20% change in plasma levels of the biomarkers [10]. Baseline and procedural variables are presented as mean with standard deviation or median with interquartile range for non-Gaussian distributed data. Biochemical parameters are all presented as median with interquartile range for non-Gaussian distributed data. Spearman correlations were used to assess associations between variables. Wilcoxon signed ranks test was used to evaluate time-dependent changes in biochemical parameters. Two-tailed P-values <0.05 were considered as statistically significant. No formal statistical tests were used to address the issue of multiple comparisons. However, given the large number of tests performed, thoughtful consideration of the specific context, the pre-test probability and the biological plausibility of each statistically significant association was an important issue. All statistical analyses were performed using SPSS version 17 (SPSS Inc., Chicago, USA).

Results

We included 46 patients of whom 24 received placebo and 22 FX06 treatment. There were no differences between the FX06 treated group and the placebo group in the levels of any of the...
Plasma Levels of sTNFR1, sTNFR2, sFAS, sFASL, MMPs, TIMPs and MPO During the First 24 hours in STEMI Patients Undergoing Primary PCI

Plasma levels of sTNFR1, sTNFR2, sFAS, sFASL, MMP-2, MMP-8, MMP-9, TIMP-1, TIMP-2 and MPO at 0 and 24 hours, as well as the change in plasma levels over time, are summarized in table 2. Of note, TNFR1, TNFR2 and FAS all increased significantly from baseline to 24 hours, whereas FAS ligand decreased over time. The data on MMPs, TIMPs and MPO have been published elsewhere [10]. Plasma levels of soluble markers of apoptosis were also measured in an age-matched control group (n = 32). The median (25th percentile, 75th percentile) levels were 2160 pg/mL (1921, 2258) for sTNFR1, 6758 pg/mL (6273, 7077) for sFAS, and 46.7 pg/mL (43.0, 50.3) for sFASL, respectively. These levels were very similar to and did not differ significantly from the plasma levels of STEMI patients at 0 hours (data not shown).

Correlations between sTNFR1, sTNFR2, sFAS and sFASL and Measures of Infarct Size

The infarct size, defined as the late gadolinium enhancement zone (LGE zone) on CMR examination, was assessed at five days and four months after STEMI and primary PCI. All study participants were included in the day five examination, whereas 9 of the 46 patients did not complete the MRI at four months. Correlations between sTNFR1, sTNFR2, sFAS, sFASL and LGE zone are summarized in table 3. Soluble TNFR1 at baseline did not correlate with infarct size, whereas sTNFR1 at 24 hours tended to correlate with infarct size at 5 days and showed a significant positive correlation with infarct size measured at 4 months. Also, the relative change in sTNFR1 levels from 0 to 24 hours correlated significantly with infarct size at 5 days and 4 months. Similar but weaker correlations were seen for sTNFR2. Both sFAS and sFASL at 0 and 24 hours showed a tendency towards a negative correlation with infarct size, especially infarct size at 5 days, but none of those correlations were statistically significant.

Correlations between sTNFR1, sTNFR2, sFAS and sFASL and Measures of Left Ventricular Dysfunction and Remodeling

Findings are summarized in table 4. Of interest, sTNFR1 at 24 hours as well as the relative change in sTNFR1 from 0 to 24 hours,

| Table 1. Baseline, procedural and outcome measures of the study population (n = 46). |
|---------------------------------------------------------------|

| Baseline variables | Age, years (mean, SD) | 61 (11) |
|--------------------|-----------------------|---------|
| Female, % (n)      | 35 (16)               |         |
| Body-mass index, kg/m² (mean, SD) | 27 (3.5) |         |
| Anterior infarct location, % (n) | 46 (21) |         |
| Time-to-PCI, minutes (median, 25th, 75th percentile) | 152 (115, 280) |         |

| Procedural variables | TIMI pre-procedural, % (n) |
|----------------------|---------------------------|
| 0                    | 98 (45)                   |
| 1                    | 2 (1)                     |
| TIMI after PCI, % (n) | 2 (3)                     |
| 3                    | 94 (43)                   |

| Medications | Glycoprotein IIb/IIIa, % (n) | 78 (36) |
|-------------|------------------------------|---------|
| Aspirin, % (n) | 98 (45)                     |         |
| Betablockers, % (n) | 100 (46)                  |         |
| Clopidogrel, % (n) | 100 (46)                  |         |

| Outcomes | Infarct size at 5 days, g (median, 25th, 75th percentile) | 35 (14, 53) |
|---------|----------------------------------------------------------|------------|
| Infarct size at 4 months, g (median, 25th, 75th percentile) | 23 (6.0, 38) |
| LVEF at 5 days, % (median, 25th, 75th percentile) | 45 (40, 52) |
| LVEF at 4 months, % (median, 25th, 75th percentile) | 50 (45, 57) |
| EDVI at 5 days, ml³ (median, 25th, 75th percentile) | 79 (64, 87) |
| EDVI at 4 months, ml³ (median, 25th, 75th percentile) | 79 (63, 90) |
| ESVI at 5 days, ml³ (median, 25th, 75th percentile) | 44 (31, 50) |
| ESVI at 4 months, ml³ (median, 25th, 75th percentile) | 38 (28, 48) |

| Table 2. Plasma levels of sTNFR1, sTNFR2, sFAS, sFASL, MMPs, TIMPs and MPO during the first 24 hours after STEMI and reperfusion treatment (n = 46). |
|---------------------------------------------------------------|

| Procedural variables | 0 h | 24 h | change (%) | p-value |
|----------------------|-----|------|------------|---------|
| sTNFR1 (pg/mL)       | 1256 (1039, 1481) | 1617 (1216, 1890) | 26 (9.0, 40) | p<0.001 |
| sTNFR2 (pg/mL)       | 2170 (1787, 2570) | 2451 (1982, 3269) | 14 (–0.4, 24) | P<0.001 |
| sFAS (pg/mL)         | 6527 (5375, 8093) | 7685 (6146, 8655) | 9.9 (–2.7, 27) | P<0.001 |
| sFASL (pg/mL)        | 45.3 (35.5, 50.0) | 43.6 (35.7, 51.8) | 5.3 (–12, 27) | P = 0.029 |
| MMP-2 (ng/mL)        | 196 (172, 222) | 191 (161, 216) | 5 (–14, 4) | P = 0.193 |
| MMP-8 (ng/mL)        | 4.0 (2.2, 5.8) | 3.9 (1.8, 6.9) | –6 (–60, 102) | P = 0.808 |
| MMP-9 (ng/mL)        | 89 (43, 135) | 62 (31, 153) | –35 (–65, 45) | P = 0.121 |
| TIMP-1 (ng/mL)       | 75 (70, 88) | 98 (84, 128) | 29 (16, 52) | P<0.001 |
| TIMP-2 (ng/mL)       | 67 (61, 74) | 64 (56, 72) | 4 (–15, 3) | P = 0.024 |
| MPO (ng/mL)          | 1245 (260, 1628) | 428 (198, 727) | –65 (–82, –31) | P<0.001 |

Values are given as median (25th, 75th percentile). P-values are shown for Wilcoxon signed ranks test. sTNFR1, soluble tumour necrosis factor receptor 1; sTNFR2, soluble tumour necrosis factor receptor 2; sFAS, soluble FAS; sFASL, soluble FAS ligand; MMP-2, matrix metalloproteinase-2; TIMP, tissue inhibitor of metalloproteinase; MPO, myeloperoxidase; STEMI, ST-elevation myocardial infarction.
doi:10.1371/journal.pone.0055477.t001

doi:10.1371/journal.pone.0055477.t002

doi:10.1371/journal.pone.0055477.t003

doi:10.1371/journal.pone.0055477.t004
Table 3. Correlations between sTNFR1, sTNFR2, sFAS and sFASL and measures of infarct size.

| sTNFR1 | Total LGE at 5 days | Total LGE at 4 months |
|--------|---------------------|----------------------|
| 0 h    | 0.014               | 0.037                |
| 24 h   | 0.231               | 0.358*               |
| % change | 0.412*             | 0.385*               |

| sTNFR2 | Total LGE at 5 days | Total LGE at 4 months |
|--------|---------------------|----------------------|
| 0 h    | 0.005               | 0.034                |
| 24 h   | 0.138               | 0.203                |
| % change | 0.356*             | 0.369*               |

| sFAS   | Total LGE at 5 days | Total LGE at 4 months |
|--------|---------------------|----------------------|
| 0 h    | −0.150              | −0.039               |
| 24 h   | −0.304              | −0.099               |
| % change | −0.242              | 0.007                |

| sFASL  | Total LGE at 5 days | Total LGE at 4 months |
|--------|---------------------|----------------------|
| 0 h    | −0.236              | −0.192               |
| 24 h   | −0.210              | −0.174               |
| % change | 0.036               | 0.021                |

Values are given as rho-values from Spearman test.

Table 4. Correlations between sTNFR1, sTNFR2, sFAS and sFASL and measures of left ventricular dysfunction and remodeling.

| sTNFR1 | LVEF% at 5 days | LVEF% at 4 months | dEDVI | dESVI |
|--------|-----------------|-------------------|-------|-------|
| 0 h    | −0.048          | −0.177            | −0.070| 0.097 |
| 24 h   | −0.200          | −0.354*           | −0.237| −0.067|
| % change | −0.274          | −0.375*           | −0.285| −0.253|

| sTNFR2 | LVEF% at 5 days | LVEF% at 4 months | dEDVI | dESVI |
|--------|-----------------|-------------------|-------|-------|
| 0 h    | −0.017          | −0.155            | −0.119| 0.071 |
| 24 h   | −0.078          | −0.253            | −0.160| −0.014|
| % change | −0.125          | −0.192            | −0.045| −0.159|

| sFAS   | LVEF% at 5 days | LVEF% at 4 months | dEDVI | dESVI |
|--------|-----------------|-------------------|-------|-------|
| 0 h    | −0.022          | −0.075            | 0.061 | 0.210 |
| 24 h   | −0.264          | −0.258            | 0.171 | 0.196 |
| % change | 0.048           | −0.078            | 0.173 | −0.005|

| sFASL  | LVEF% at 5 days | LVEF% at 4 months | dEDVI | dESVI |
|--------|-----------------|-------------------|-------|-------|
| 0 h    | −0.257          | −0.228            | 0.035 | 0.175 |
| 24 h   | −0.249          | −0.168            | −0.106| 0.057 |
| % change | −0.016          | 0.087             | −0.202| −0.194|

Values are given as rho-values from Spearman test.

Table 5. Correlations between sTNFR1, sTNFR2, sFAS, sFASL and Troponin I and MMP-2.

| sTNFR1 | Troponin I at 24 hours | MMP-2 at 24 hours |
|--------|------------------------|-------------------|
| 0 h    | 0.101                  | 0.397**            |
| 24 h   | 0.615**                | 0.595**            |
| % change | 0.613**               | 0.478**            |

| sTNFR2 | Troponin I at 24 hours | MMP-2 at 24 hours |
|--------|------------------------|-------------------|
| 0 h    | 0.072                  | 0.311*            |
| 24 h   | 0.553**                | 0.595**            |
| % change | 0.550**               | 0.493**            |

| sFAS   | Troponin I at 24 hours | MMP-2 at 24 hours |
|--------|------------------------|-------------------|
| 0 h    | −0.125                 | 0.182             |
| 24 h   | 0.136                  | 0.582**            |
| % change | 0.368*                | 0.481**            |

| sFASL  | Troponin I at 24 hours | MMP-2 at 24 hours |
|--------|------------------------|-------------------|
| 0 h    | −0.103                 | −0.458**           |
| 24 h   | −0.064                 | −0.387**           |
| % change | 0.046                 | 0.194              |

Values are given as rho-values from Spearman test.

Discussion

The main finding of the study was the consistent and significant correlation between 24 hour levels of plasma sTNFR1 and outcome measures of infarct size and LV-dysfunction. Individuals with the highest levels of sTNFR1 ended up with the largest infarcts and developed a more pronounced LV-dysfunction, which are both markers of a poor prognosis. Similar but weaker and non-significant trends were found for 24 hour levels of sTNFR2. However, the relative increases in sTNFR1 and sTNFR2 over 24 hours were both significantly correlated with infarct size and LV-dysfunction. Notably, plasma soluble FAS and FAS ligand did not consistently correlate with any of the outcome measures.

Several experimental studies have demonstrated the role of TNF signaling in myocardial cell apoptosis leading to IR-injury, LV dysfunction and congestive heart failure [28]. However, data from animal models show conflicting results. In one study, TNF overexpression in mice promotes the development of post-
myocardial infarction left ventricular remodelling and contractile dysfunction [29], whereas other studies demonstrates the protective role of TNF signaling on myocardial cell apoptosis and on reducing infarct size [30,31]. While high doses of exogenous TNF renders both ischemic pre- and postconditioning less efficient, pre-ischemic neutralization of TNF reduces infarct size in rabbits and local delivery of sTNFR1 gene reduces infarct size following IR-injury in rats [32–34]. A cardioprotective mechanism seems to be conveyed by the TNFR2 receptor when binding to TNF, especially if ligand levels are low [35]. The conflicting results also found in studies on rats further highlight the complexity of the anti-versus proapoptotic properties of TNF signaling [36,37]. The discrepancies found between different animal models might have several possible explanations. For example, the degree of TNF overexpression varies between animal models and might result in differences in TNFR1 versus TNFR2 activation, resulting in divergent effects on apoptosis. Also, some studies use cardiomyocyte-restricted overexpression of TNF, whereas others overexpress TNF in several cell types (including endothelial cells) possibly leading to different effects on apoptosis during IR-injury. The present study was not designed to evaluate whether TNF signaling exerts anti- or proapoptotic properties, but rather to study correlations between soluble markers of apoptosis and measures of infarct size.

In the present study, we choose to measure sTNFRs instead of TNF in plasma. Data indicate that sTNFRs correlate well with circulating TNF, which due to short half-life in plasma is a less reliable marker [38,39]. To our knowledge, this is the first study in a pure STEMI population to show the positive association between sTNFR1 in plasma and the extent of the final infarct size. However, these results are in line with previous clinical studies on acute myocardial infarction demonstrating the role of sTNFR1 in predicting mortality and new-onset heart failure [15,16].

In a previous study on acute myocardial infarction patients, sFAS and sFASL showed no correlation with infarct size, as measured by plasma levels of creatine phosphokinase and of myosin light chain type I [14]. However, sFAS did correlate with hemodynamic measures of heart failure. In our study, including a homogenous STEMI population, sFAS and sFASL did not show any consistent correlations with infarct size, LV-dysfunction or measures of remodeling. However, this does not exclude a role of the FAS/FASL pathway in IR-injury of the myocardium. The time points for analysis of sFAS and sFASL in the present study (at baseline and 24 hours) might not be the optimal in reflecting activation of the FAS/FASL pathway.

Experimental data have demonstrated that intracellular MMP-2 activation in response to oxidative stress might be an important mechanism of triggering cardiomyocyte apoptosis [11]. TNF has been found to provoke cardiomyocyte apoptosis and cardiac remodeling through activation of both intrinsic and extrinsic cell death pathways [40]. In a transgenic mice model with cardiac-restricted overexpression of TNF, there was a significant increase in total MMP activity during the early phase of LV-remodelling [41]. In a previous substudy of the F.I.R.E. trial, we showed a strong positive correlation between plasma levels of MMP-2 and infarct size and LV dysfunction [10]. In the present study, we find a strong positive correlation between plasma MMP-2 levels and all the measured soluble markers of apoptosis. This further strengthens the role of apoptosis in IR-injury.

Left ventricular remodeling was assessed by calculating changes in endystolic and enddiastolic left ventricular volume indices (dESVI and dEDVI) from day 5 to 4 months after STEMI. None of the soluble markers of apoptosis showed significant correlation with these measures of remodeling. The lack of association between sTNFRs and remodeling, despite correlation with infarct size and left ventricular dysfunction (LVEF), have several possible explanations. The process of remodeling, occurring over a longer period of time, might involve pathways not dependent of TNF signaling or might not be determined by the early increase in TNF activation following STEMI. Furthermore, in this homogenous STEMI population of patients arriving at the PCI lab within 6 hours of symptom onset and receiving state of the art treatment both in the acute phase and during follow up, infarct sizes were overall rather small and the process of remodeling might have been inhibited to a large degree.

The present study was designed and sized to analyze the effect of FX-06 on soluble markers of apoptosis. No significant differences or trends to differences were found between the treatment groups. Also, the F.I.R.E-study had an overall negative result with no effect of FX-06 on primary or secondary outcomes [18]. Thus, we think it is well justified to analyze all study participants together as one group in relation to outcome measures.

The present study has some limitations. First, there were no prior studies available on soluble markers of apoptosis and cardiac MR measurements to use for power calculations. Therefore, we calculated power based on previous data of biomarkers (MMPs, TIMPs, and TNFR1s), suggesting a sample size of 42 individuals would be adequate. The same power calculation was used in a previously published substudy of the F.I.R.E. trial, where we could detect differences in infarct size and LV-dysfunction in relation to biomarker levels [10]. Nevertheless, we cannot exclude the possibility that the size of the substudy population was too small to detect minor differences in cardiac MR measures, especially since the biomarkers had a non-normal distribution with values within a rather wide range. Secondly, study participants were randomly assigned to receive FX-06 or placebo as adjunctive therapy. Since FX-06 did not have an impact on primary or secondary outcomes in the F.I.R.E.study and did not affect levels of biomarkers in our substudy, we decided to use all patients as one group for the correlation studies. However, we cannot totally exclude the possibility that some minor effects of FX-06 influence the associations between biomarkers and measures of infarct size, LV-dysfunction and remodeling. Thirdly, the increase of circulating soluble TNF receptors is most likely not a cause, but rather a consequence, of an enhanced apoptosis, where apoptotic cells release soluble receptors into the circulation. Furthermore, levels of circulating soluble TNF receptors may not just reflect apoptosis of myocardial cells, but other cell types may also undergo apoptosis during the ischemia-reperfusion phase of STEMI. In addition, soluble TNFRs can also be generated as a result of release from cells of exosome-like vesicles independent of apoptosis [42].

To summarize, in a homogenous STEMI population we find that 24 hour levels of sTNFR1 as well as the relative changes in sTNFR1 and sTNFR2 from 0 to 24 hours are associated with myocardial infarct size as well as left ventricular dysfunction at follow-up. This indicates that apoptosis might be a determinant of the extent of IR-injury. The relative importance of apoptosis versus necrosis during IR-injury needs to be further investigated.

Acknowledgments

The authors thank Professor Peter Buser and Dr Jens Bremerich (University Hospital Basel, Basel, Switzerland) for reading cardiac magnetic resonance images. We are grateful to Ylva Lindegardh for excellent technical assistance.
Author Contributions
Conceived and designed the experiments: LN AS LJ. Performed the experiments: LN AS LJ. Analyzed the data: LN AS ES LJ. Contributed reagents/materials/analysis tools: LN AS ES LJ. Wrote the paper: LN AS ES LJ.

References
1. Thatcher JL, Gilheath TA, Adlis S (2003) Improved efficiency in acute myocardial infarction care through commitment to emergency department initiated primary PCI. J Invasive Cardiol 15: 693–698.
2. Kesely EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361: 13–20.
3. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357: 1121–1135.
4. Piper HM, Meuter K, Schafer C (2003) Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 75: 864–849.
5. Eltzhig HK, Eckle T (2011) Ischemia and reperfusion-from mechanism to translation. Nat Med 17: 1391–1401.
6. Olivetti G, Quaini F, Sala R, Lagrasta C, Gorradi D, et al. (1996) Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 28: 2905–2016.
7. Saraste A, Pulkkki K, Kallajoki M, Henriksen K, Parvinen M, et al. (1997) Apoptosis in human acute myocardial infarction. Circulation 95: 320–323.
8. Gotlieb RA, Burleson KO, Kloser RA, Babior BM, Engler RL. (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94: 1621–1628.
9. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, et al. (1997) Apoptosis in the failing human heart. N Engl J Med 336: 1131–1141.
10. Nilsson L, Hallen J, Arat D, Jonasson L, Swahn E (2012) Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 98: 31–36.
11. Kandasamy AD, Chow AK, Ali MA, Schulz R (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85: 413–423.
12. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770–776.
13. Weinlich R, Brunner T, Amarante-Mendes GP (2010) Control of death receptor cell death by posttranslational modifications. Cell Mol Life Sci 67: 1631–1642.
14. Ohhata T, Hamada M, Sasaki O, Suzuki M, Hara Y, et al. (1999) Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Coron Artery Dis 10: 221–225.
15. Valgimigli M, Cecconi M, Malagutti P, Merli E, Soukhomovskaia O, et al. (2005) Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation 111: 863–870.
16. Ueland T, Kjekshus J, Frøland SS, Omland T, Squire IB, et al. (2005) Plasma matrix metalloproteinase-2 predicts infarct size and ventricular dysfunction in infarction care through commitment to emergency department initiated primary PCI. J Invasive Cardiol 15: 693–698.
17. Atar D, Petzelbauer P, Kuch A, Menumann J, Zacharowski PA, et al. (2007) The fibrin-derived peptide Ibta3-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury. Crit Care Med 35: 1730–1735.
18. Dall’Armellina E, Karamitros TD, Neuhauser S, Choulhury RP (2010) CMR for characterization of the myocardium in acute coronary syndromes. Nat Rev Cardiol 7: 624–636.
19. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, et al. (2008) Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: a meta-analysis of individual patient data from 25 randomized trials. Am Heart J 156: 404–410.
20. Van de Werf F, Arzoumanian D, Betriu A, Cokkinos DV, Falk E, et al. (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24: 28–46.
21. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, et al. (2004) Reduced myocardial reperfusion injury in myocardial ischemia-reperfusion injury. Ann Thorac Surg 75: 864–849.
22. Bryant D, Becker I, Richardson J, Sherlon J, Franco F, et al. (1996) Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97: 1375–1381.
23. Kryuleynik KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, et al. (2000) Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 97: 5456–5461.
24. Burchfield JS, Dong JW, Sakata Y, Gao F, Tseng HP, et al. (2010) The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ Heart Fail 3: 157–164.
25. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, et al. (2002) Identification of a novel role for sphingolipid signaling in TNF alpha and ischemia preconditioning mediated cardioprotection. J Mol Cell Cardiol 34: 509–518.
26. Belosorov S, Boll I, Duschn A, Heuschk G, Schulz R (2003) TNF-alpha antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. Am J Physiol Heart Circ Physiol 284: H927–930.
27. Sugano M, Hata T, Tsuchida K, Sato S, Oyama J, et al. (2004) Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats. Mol Cell Biochem 266: 127–132.
28. Bocchi V (1991) Interleukins. Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 21: 274–276.
29. Bryant D, Becker I, Richardson J, Shelton J, Franco F, et al. (1996) Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor. Circulation 97: 1375–1381.
30. Saraste A, Pulkkki K, Kallajoki M, Henriksen K, Parvinen M, et al. (1997) Apoptosis in human acute myocardial infarction. Circulation 95: 320–323.
31. Kandasamy AD, Chow AK, Ali MA, Schulz R (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85: 413–423.
32. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770–776.
33. Weinlich R, Brunner T, Amarante-Mendes GP (2010) Control of death receptor cell death by posttranslational modifications. Cell Mol Life Sci 67: 1631–1642.
34. Ohhata T, Hamada M, Sasaki O, Suzuki M, Hara Y, et al. (1999) Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Coron Artery Dis 10: 221–225.
35. Valgimigli M, Cecconi M, Malagutti P, Merli E, Soukhomovskaia O, et al. (2005) Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation 111: 863–870.
36. Ueland T, Kjekshus J, Frøland SS, Omland T, Squire IB, et al. (2005) Plasma matrix metalloproteinase-2 predicts infarct size and ventricular dysfunction in infarction care through commitment to emergency department initiated primary PCI. J Invasive Cardiol 15: 693–698.
37. Atar D, Huber K, Ruprecht HJ, Kopeczy SL, Schwitzer J, et al. (2007) Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Ibta3-42) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Cardioiology 108: 117–123.
38. Atar D, Petzelbauer P, Schwitzer J, Huber K, Rensing B, et al. (2008) Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 53: 729–729.
39. Frangogiannis NG, Smith CW, Enman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31–47.
40. Kakkar AK, Lefler DJ (2004) Leukocyte and endothelial adhesion molecule interactions in myocardial ischemia-reperfusion injury. Ann Thorac Surg 75: 864–849.
41. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, et al. (2004) Release of full-length TNF Receptors, Infarct Size and LV Dysfunction